Kymera Therapeutics (KYMR) is back in focus after sharing new data on its protein degrader pipeline, including Phase 1 results for KT-621 in healthy Japanese adults and expanded preclinical findings for lupus candidate KT-579.

Kymera Therapeutics’ recent KT-621 and KT-579 readouts arrive after a period of strong momentum, with the latest share price at $90.43, a 30 day share price return of 14.63% and a one year total shareholder return of 97.14%, alongside a very large three year total shareholder return.

If you are interested in how other healthcare stocks are trying to reshape treatment with similar tools, it could be worth scanning a curated set of 40 healthcare AI stocks

With Kymera Therapeutics up 97.14% over the past year and trading at $90.43, alongside a value score of 2 and a 31.8% discount to the average analyst price target, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 24.1% Undervalued

Kymera Therapeutics’ most followed valuation narrative points to a fair value of about $119 per share versus the last close at $90.43, framing a sizeable gap that hinges on how its oral degrader pipeline develops over time.

The anticipated Phase II and III trials for their immunology pipeline aim to deliver biologics-like efficacy in oral form, which could enhance net margins by reducing manufacturing costs associated with biologics and potentially capturing a larger market share.

Want to see what justifies that kind of valuation gap? The narrative leans heavily on future revenue mix, margin uplift, and a very rich earnings multiple. The exact assumptions may surprise you.

Result: Fair Value of $119.19 (UNDERVALUED)

However, Kymera Therapeutics still faces execution risk if high R&D spending does not translate into successful drugs. In addition, partnership setbacks could quickly challenge the current undervaluation story.

Next Steps

With both risks and rewards in play for Kymera Therapeutics, it makes sense to move quickly, review the data, and decide where you stand based on the 2 key rewards and 4 important warning signs highlighted in the 2 key rewards and 4 important warning signs.

Looking for more Kymera Therapeutics style investment ideas?

Do not stop at Kymera Therapeutics. Use the Simply Wall St Screener to spot fresh opportunities before they become crowded trades and leave you watching from the sidelines.

• Target stronger balance sheets and fundamentals by running stocks through the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for quality at a discount by scanning the 45 high quality undervalued stocks that combine solid businesses with pricing that may appeal to value focused investors.
• Unearth lesser known opportunities with the screener containing 19 high quality undiscovered gems that might not yet be widely followed but already show strong underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.